alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Order entered April 20, 2016

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 14
- 00856
- CV
IN THE INTEREST OF C.S.B AND R.D.B, CHILDREN On Appeal from the 255th Judicial District Court

Dallas County, Texas Trial Court Cause No. DF
- 11
- 15158



### O RDER
We GRANT appellee’s April 18, 2016 second motion for an extension of time to file a brief. Appellee shall file a brief by MAY 25, 2016 . We caution appellee that no further extension will be granted absent extenuating circumstances.

/s/ ELIZ ABETH LANG

- MIERS JUSTICE
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 01-40703

Summary Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

CARL ESTER BECK;

BOBBY DEWAYNE JONES,

Defendants-Appellants.

--------------------

Appeal from the United States District Court

for the Eastern District of Texas

USDC No. 6:00-CR-77-1

--------------------

June 6, 2002

Before JONES, SMITH, and EMILIO M. GARZA, Circuit Judges.

PER CURIAM:*

Carl Ester Beck appeals the judgment of the district court

following his conviction for conspiracy to distribute cocaine

base and distribution of cocaine base. Bobby Dewayne Jones

appeals the judgment of the district court following his

conviction for conspiracy to distribute cocaine base and

distribution of cocaine base near a school. 
No. 01-40703

-2-

Beck argues that the evidence was insufficient to support

his conspiracy conviction. Beck has not shown that the evidence

adduced at trial, when viewed in the light most favorable to the

verdict, was insufficient to prove beyond a reasonable doubt that

he was involved with a conspiracy to distribute crack cocaine. 

See United States v. Ortega-Reyna, 148 F.3d 540, 543 (5th Cir.

1998); United States v. Dukes, 139 F.3d 469, 474 (5th Cir. 1998). 

Beck also argues that the district court erred in sentencing him

based on its finding that he committed an offense involving crack

cocaine. He has not shown error in connection with his sentence. 

See United States v. Vital, 68 F.3d 114, 120 (5th Cir. 1995). 

Jones argues that the evidence was insufficient to support

his conspiracy conviction. He has not shown that the evidence

adduced at trial, when viewed in the light most favorable to the

verdict, was insufficient to prove beyond a reasonable doubt that

he was involved with a conspiracy to distribute crack cocaine. 

See Ortega-Reyna, 148 F.3d at 543. The judgments of the district

court are AFFIRMED.
Order entered May 20, 2021

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-21-00166-CV

PAUL BRADLEY “BRAD” JOWELL, Appellant

V.

BIOTE MEDICAL. LLC, Appellee

On Appeal from the 192nd Judicial District Court

Dallas County, Texas

Trial Court Cause No. DC-20-18668

ORDER

Before the Court is appellee’s May 19, 2021 motion for an extension of time 

to file its brief on the merits. We GRANT the motion and extend the time to June 

18, 2021. We caution appellee that further extension requests in this accelerated 

appeal will be disfavored.

/s/ BONNIE LEE GOLDSTEIN

JUSTICE
<TABLE> <S> <C>

<ARTICLE>                     5
<MULTIPLIER>                  1
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                              DEC-31-1996
<PERIOD-END>                                   DEC-31-1996
<CASH>                                                   0
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                         0
<PP&E>                                                   0
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                 160,009,000
<CURRENT-LIABILITIES>                                    0
<BONDS>                                                  0
<PREFERRED-MANDATORY>                          160,000,000
<PREFERRED>                                              0
<COMMON>                                             9,000
<OTHER-SE>                                               0
<TOTAL-LIABILITY-AND-EQUITY>                   160,009,000
<SALES>                                                  0
<TOTAL-REVENUES>                                 6,183,681
<CGS>                                                    0
<TOTAL-COSTS>                                    6,183,681
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                          0
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      0
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                             0
<EPS-PRIMARY>                                            0
<EPS-DILUTED>                                            0
        



</TABLE>
I 

114TH CONGRESS 

1ST SESSION H. R. 2294 

To amend title 38, United States Code, to make memorial headstones and 

markers available for purchase on behalf of members of reserve components who performed inactive duty training or active duty for training 

but did not serve on active duty. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 13, 2015 

Mr. SEAN PATRICK MALONEY of New York introduced the following bill; 

which was referred to the Committee on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to make memorial 

headstones and markers available for purchase on behalf 

of members of reserve components who performed inactive duty training or active duty for training but did 

not serve on active duty. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Honor Guardsmen and 

5 Reservists Act’’. 


emcdonald on DSK67QTVN1PROD with BILLS
2 

•HR 2294 IH

1 SEC. 2. AVAILABILITY FOR PURCHASE OF DEPARTMENT OF 

2 VETERANS AFFAIRS MEMORIAL HEADSTONES 

3 AND MARKERS FOR MEMBERS OF RESERVE 

4 COMPONENTS WHO PERFORMED CERTAIN 

5 TRAINING. 

6 Section 2306 of title 38, United States Code, is 

7 amended by adding at the end the following new sub8 section: 

9 ‘‘(i)(1) The Secretary shall make available for pur10 chase a memorial headstone or marker for the marked or 

11 unmarked grave of an individual described in paragraph 

12 (2) or for the purpose of commemorating such an indi13 vidual whose remains are unavailable. 

14 ‘‘(2) An individual described in this paragraph is an 

15 individual who— 

16 ‘‘(A) as a member of a reserve component per17 formed inactive duty training or active duty for 

18 training, but did not serve on active duty; and 

19 ‘‘(B) is not otherwise ineligible for a memorial 

20 headstone or marker on account of the nature of the 

21 individual’s separation from the Armed Forces or 

22 other cause.’’. 

Æ 


emcdonald on DSK67QTVN1PROD with BILLS
# C_2021006EN.01000501.xml

| 8.1.2021 | EN | Official Journal of the European Union | C 6/5 |
| --- | --- | --- | --- |

8.1.2021

EN

Official Journal of the European Union

C 6/5

---

Non-opposition to a notified concentration

(Case M.9983 — Magna/GFT Bordeaux)

(Text with EEA relevance)

(2021/C 6/03)

On 22 December 2020, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32020M9983. EUR-Lex is the on-line access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32020M9983. EUR-Lex is the on-line access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
# C_2021136EN.01000401.xml

| 19.4.2021 | EN | Official Journal of the European Union | C 136/4 |
| --- | --- | --- | --- |

19.4.2021

EN

Official Journal of the European Union

C 136/4

---

Notice for the attention of certain persons and entities subject to the restrictive measures provided for in Council Decision 2010/413/CFSP and Council Regulation (EU) No 267/2012 concerning restrictive measures against Iran

(2021/C 136/03)

The following information is brought to the attention of Mr Anis NACCACHE (No 13), Mr. Davoud BABAEI (No 23), Armed Forces Geographical Organisation (No 2), Shahid Ahmad Kazemi Industrial Group (No 38) and Organisation of Defensive Innovation and Research (SPND) (No 153), persons and entities appearing in Annex II, Part I, to Council Decision 2010/413/CFSP (1) and in Annex IX, Part I, to Council Regulation (EU) No 267/2012 (2) concerning restrictive measures against Iran.

The following information is also brought to the attention of Rear Admiral Ali FADAVI (no 2) and Mr. Mohammad Ali JAFARI (No 6), persons appearing in Annex II, Part II, to Decision 2010/413/CFSP and in Annex IX, Part II, to Regulation (EU) No 267/2012 concerning restrictive measures against Iran.

The Council intends to maintain the restrictive measures against the above-mentioned persons and entities with new statements of reasons. The persons and entities concerned are hereby informed that they may submit a request to the Council to obtain the intended statement of reasons for their designation, by 28 April 2021, to the following address:

| Council of the European Union |
| --- |
| General Secretariat |
| RELEX.1.C |
| Rue de la Loi/Wetstraat 175 |
| 1048 Bruxelles/Brussel |
| BELGIQUE/BELGIË |
| Email: sanctions@consilium.europa.eu |

Council of the European Union

General Secretariat

RELEX.1.C

Rue de la Loi/Wetstraat 175

1048 Bruxelles/Brussel

BELGIQUE/BELGIË

Email: sanctions@consilium.europa.eu

---

(1)  OJ L 195, 27.7.2010, p. 39.

(2)  OJ L 88, 24.3.2012, p. 1.

---
EXHIBIT 31.1

Certification

I, Kevan Casey, certify that:

1.     I have reviewed this Form 10-QSB of eLinear, Inc.;

2.     Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the small business
issuer as of, and for, the periods presented in this report;

4.     The small business issuer's other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and
15d-15(f)) for the small business issuer and have:

a.     Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the small business issuer,
including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being
prepared;

b.     Designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;

c.     Evaluated the effectiveness of the small business issuer's disclosure
controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and

5.     The small business issuer's other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over
financial reporting, to the small business issuer's auditors and the audit
committee of the small business issuer's board of directors (or persons
performing the equivalent functions):

a.     All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the small business issuer's ability to record,
process, summarize and report financial information; and

b.     Any fraud, whether or not material, that involves management or other
employees who have a significant role in the small business issuer's internal
control over financial reporting.

Date: August 23, 2004


/s/ Kevan Casey
------------------------------
Kevan Casey, Chief Executive Officer


<PAGE>
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-897]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: Aurobindo Pharma USA, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 13, 2021. Such persons may also file a written request for a hearing on the application on or before October 13, 2021.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on July 20, 2021, Aurobindo Pharma USA, Inc., 6 Wheeling Road, Dayton, New Jersey 08810-1526, applied to be registered as an importer of the following basic class(es) of controlled substance(s): Controlled substance
Drug code
ScheduleRemifentanil
9739
II
 The company plans to import Remifentanil (9739) in bulk form for research and development. No other activity for this drug code is authorized for this registration. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Brian S. Besser, Acting Assistant Administrator.


[FR Doc. 2021-19631 Filed 9-10-21; 8:45 am] BILLING CODE P
```

[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2308 Introduced in House (IH)]

114th CONGRESS
  1st Session
                                H. R. 2308

       To designate a peak located in Nevada as ``Mount Reagan''.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 13, 2015

  Mr. Hardy introduced the following bill; which was referred to the 
                     Committee on Natural Resources

_______________________________________________________________________

                                 A BILL

 
       To designate a peak located in Nevada as ``Mount Reagan''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DESIGNATION OF MOUNT REAGAN.

    (a) Designation.--The peak in the State of Nevada located at N 
36.18804 W 114.99815 shall be designated as ``Mount Reagan''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the peak referred to in 
subsection (a) shall be deemed to be a reference to Mount Reagan.
                                 <all>
```
Skip to main content

Privacy Policy•Site map

# Site Map

                                    -  
                                    - Home
                                    - Courthouse                                       - Courtroom Technology
                                      - Directory
                                      - Hours of Operations/ Directions
                                      - Courtroom Decorum
                                      - Guidance for In-Person Proceedings
                                    - About the Court                                       - History
                                      - Frequently Asked Questions
                                      - Job Opportunities/ Employment
                                      - Reports/Statistics
                                      - Seminars Disclosure
                                      - Surveys
                                    - Judges
                                    - Special Masters
                                    - Events                                       - 2023 World Intellectual Property Day
                                      - 17th Annual Law Day Luncheon
                                      - 34th Annual Judicial Conference
                                    - Scheduled Matters
                                    - 
                                    - 
                                    - 
                                    - 
                                    - 
                                    - 
CM/ECF Resources
Attorney Information
Vaccine Claims
Survey

Howard T. Markey National Courts Building • 717 Madison Place, NW, Washington, DC 20439 • 202-357-6400
Filed 7/13/10 by Clerk of Supreme Court

IN THE SUPREME COURT

STATE OF NORTH DAKOTA

2010 ND 129

State of North Dakota, Plaintiff and Appellee

v.

James Michael Everett, Defendant and Appellant

No. 20090386

Appeal from the District Court of Grand Forks County, Northeast Central Judicial District, the Honorable Lawrence E. Jahnke, Judge.

AFFIRMED.

Per Curiam.

Peter D. Welte, State’s Attorney, and Sean B. Kasson, third-year law student, P.O. Box 5607, Grand Forks, N.D. 58206-5607, for plaintiff and appellee; submitted on brief.

Kent M. Morrow, P.O. Box 2155, Bismarck, N.D. 58502-2155, for defendant and appellant; submitted on brief.

State v. Everett

No. 20090386

Per Curiam.

[¶1]James Michael Everett appeals from an order revoking his probation and resentencing him to five year’s incarceration with one year suspended.  On appeal, Everett argues the trial court abused its discretion by revoking his probation.  He argues the trial court should have made findings that incarceration was necessary under ABA Standards Relating to Probation, § 5.1(a).  Everett is requesting this Court to review his sentence in the context of whether he should have received probation or incarceration.  Appellate review of a sentence focuses only on whether the trial court “acted within the limits prescribed by statute, or substantially relied on an impermissible factor.”   State v. Wardner, 2006 ND 256, ¶ 27, 725 N.W.2d 215; see State v. Ennis, 464 N.W.2d 378, 382 (N.D. 1990) (“On appeal of a claim that a sentence is excessive or incorrect, this court has no power to review the discretion of a sentencing court in fixing a term of imprisonment within the range authorized by statue.”).  Because the trial court had the discretion to sentence Everett to incarceration and nothing in the record indicates the trial court relied on impermissible sentencing factors, we affirm under N.D.R.App.P. 35.1 (a)(4) and (7).

[¶2]Gerald W. VandeWalle, C.J.

Mary Muehlen Maring

Daniel J. Crothers

Dale V. Sandstrom

Carol Ronning Kapsner